Neurotech: what are startups building now?
In our neurotechnology market deck, you will find everything you need to understand the market
SUMMARY
Neurotech startups are now building practical neural systems around four main layers: implanted brain-computer interfaces, therapeutic stimulation, wearable EEG, and the hardware that makes long-term neural access possible.
The near-term market is much more medical than transhuman. The strongest products are aimed at restoring speech and digital control, improving recovery after neurological damage, treating difficult brain disorders, and monitoring patients continuously.
The biggest technical split is no longer simply invasive versus non-invasive. Startups are choosing among intracortical, cortical-surface, subdural, endovascular and scalp-based approaches, each trading neural bandwidth against surgical burden and long-term stability.
Speech restoration is becoming one of the clearest tests of serious BCI capability. It requires far richer decoding than cursor movement, while even imperfect performance can create immediate clinical value for people who have lost the ability to communicate.
Therapeutic neurotech is moving toward systems that both sense and stimulate. CorTec, Motif Neurotech and INBRAIN show how the field is shifting from passive measurement toward devices that can eventually respond to a patient's neural state.
Consumer neurotech is real, but much narrower. Wearable EEG works today for sleep, cognitive-state estimation and seizure monitoring, while high-bandwidth speech or movement decoding still depends on implanted hardware.
Materials are becoming a strategic layer of the industry. Graphene, soft polymers, ultrathin cortical films and flexible subdural interfaces matter because long-term signal quality depends on how well electronics can coexist with moving, reactive brain tissue.
The strongest startup strategy is often a platform hidden inside a narrow first indication. Companies are entering the clinic through one measurable problem such as stroke, depression or communication loss, then trying to reuse the same interface across several applications later.
AI is important, but proprietary neural access remains the scarce asset. Better decoding models become more valuable when they are paired with stable, high-quality neural data that competitors cannot easily reproduce.
The biggest unresolved problem is still the full package: high bandwidth, low surgical burden, multi-year durability, reliable autonomous use and proven clinical benefit in one system. No startup has solved all of those constraints at once.
The clearest pattern across the sector is that neurotech is becoming a stack rather than a single product category. Startups are building the materials, electrodes, implants, decoders, stimulation systems and applications needed to make neurological functions electronically addressable.
This market map, featured in our neurotechnology market deck, highlights top companies and startups in the neurotechnology market
What are neurotech startups actually building now?
Neurotech startups are currently building much more than “brain chips”: the field is converging on devices that can restore communication and movement, change dysfunctional brain activity, make neurological monitoring easier, and turn neural signals into everyday software inputs. We found four especially active product layers: implantable brain-computer interfaces for paralysis and speech loss, closed-loop neuromodulation for conditions such as depression and stroke, wearable EEG systems for clinical or consumer monitoring, and enabling hardware such as softer electrodes, graphene interfaces and specialized neural electronics.
These products are reaching very different levels of maturity. Synchron, Paradromics, CorTec and Neuralink are putting implantable systems into people but remain investigational. Precision Neuroscience already obtained FDA clearance for its Layer 7 cortical electrode array for temporary use of up to 30 days. Motif Neurotech received permission to start a first clinical trial of its tiny therapeutic implant for treatment-resistant depression. At the other end of the spectrum, Elemind and Neurable are already selling consumer products built around EEG.
The clearest map of neurotech today is a layered one. Startups are attacking different points along the neural stack, from the material touching the brain to the algorithm interpreting it and the application that finally gives the signal value.
| What startups are building | Representative companies | Main objective |
|---|---|---|
| Implantable BCIs | Neuralink, Synchron, Paradromics, Precision Neuroscience, NeuroXess | Communication and digital control |
| Therapeutic neural implants | CorTec, Motif Neurotech, INBRAIN | Treat neurological or psychiatric disease |
| Wearable neurotechnology | Elemind, Neurable, Epitel | Sleep, cognition, seizure monitoring |
| Neural-interface infrastructure | Axoft, Mint Neurotech | Better electrodes, chips and implant systems |
Is neurotech still mostly about reading the brain?
Neurotech is increasingly about both reading brain activity and changing it. The older commercial proposition was usually one-directional: measure EEG, decode an intention or monitor a neurological condition. A growing group is instead building closed-loop systems that sense neural activity, determine what is happening and then deliver stimulation intended to alter that activity.
CorTec provides an unusually clear example. Its fully implanted Brain Interchange records cortical activity and can electrically stimulate the brain through the same platform. Its lead clinical program is investigating stimulation combined with rehabilitation after chronic stroke, while the system has separately demonstrated thought-controlled computer interaction. CorTec consequently obtained FDA Breakthrough Device designations for both stroke rehabilitation and communication.
Motif Neurotech is pursuing the same general read-and-write idea from another direction. Its pea-sized DOT implant is being developed for treatment-resistant depression and is designed to stimulate networks associated with depressive symptoms from an implant that can be wirelessly powered. INBRAIN is developing graphene interfaces capable of neural recording and stimulation, while Axoft describes its own soft implant architecture as bidirectional.
Neurotech is moving toward systems that can intervene, not merely observe.
If you want more recent data on this point, please see our latest neurotechnology market report.
As this chart shows, and as featured in our neurotechnology market deck, search interest in neurotechnology has been climbing steadily
Are brain-computer interfaces finally becoming real products rather than impressive demos?
BCIs are becoming real clinical systems, but calling them mature products would still be premature. The important shift today is that several independent companies have crossed from laboratory demonstrations into structured human trials with devices designed for repeated or long-term use.
Paradromics completed the first long-term implantation in its FDA-approved Connect-One study in June 2026. Its Connexus system records from the speech motor cortex and is intended to translate neural activity into text, synthesized speech or computer commands. Synchron has moved into another generation of clinical studies after six participants completed its earlier US COMMAND trial; new studies in the United States, Canada and Australia are evaluating its endovascular Stentrode system in people with severe upper-limb impairment.
CorTec has implanted participants in an NIH-funded stroke program. Precision Neuroscience has used its surface cortical arrays in human procedures and achieved FDA clearance for the Layer 7 array for temporary implantation. NeuroXess in China has moved its fully implanted wireless system into registration-oriented clinical development after reporting multiple human implants.
The sector has moved beyond one-off demonstrations, but patient numbers remain small and deployment is still specialist-heavy.
What are invasive BCI startups actually competing on now?
Implantable BCI startups are competing over the best compromise between neural information, surgical invasiveness and long-term reliability. That trade-off explains why apparently similar companies are building radically different interfaces.
Neuralink penetrates the cortex with 64 flexible threads carrying 1,024 electrodes, maximizing direct access to neural activity while requiring robotic insertion. Paradromics also prioritizes high-data-rate intracortical recording through dense microelectrode arrays, particularly because speech decoding demands far richer information than simple binary commands.
Precision Neuroscience instead places an extremely thin electrode array on the cortical surface rather than penetrating brain tissue. NeuroXess likewise uses flexible subdural cortical electrodes. Synchron goes further toward minimizing brain surgery: its Stentrode is delivered through blood vessels and records activity from inside a cerebral vein rather than placing electrodes directly into brain tissue.
Synchron's approach shows why surgical burden is becoming part of the competitive equation. Its Stentrode reaches the brain through the vascular system, sacrificing some proximity to individual neurons for a potentially easier procedure. Precision sits between that model and intracortical systems, with a cortical-surface interface inserted through a narrow opening.
There is no settled architecture yet. The fight is over how much neural bandwidth can be retained while reducing surgical risk and improving long-term stability.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, shows annual VC investment in neurotechnology startups
Is restoring speech becoming the most important BCI application?
Speech restoration is currently emerging as one of the strongest high-bandwidth applications for implanted BCIs because it solves a devastating problem while providing a much more demanding test of the technology than moving a cursor. Paradromics has explicitly organized its first clinical program around communication, while several other BCI developers are expanding from generic computer control toward language and communication applications.
Paradromics' Connexus clinical study targets people whose speech has been severely impaired by ALS, brainstem stroke and other motor conditions. The system is intended to translate attempted or imagined speech-related activity into text, synthesized voice and computer commands. This requires continuously extracting far more information than a simple click or directional movement.
NeuroXess is also emphasizing language decoding. The company reports 71.2% accuracy for purely neural decoding across the complete set of Mandarin syllables alongside motor-control capabilities. INBRAIN's first-in-human graphene study, although primarily designed around safety during brain-tumor surgery, also captured speech-related neural patterns during awake procedures.
Speech is attractive because the clinical value is immediate: even imperfect restored communication can materially increase independence.
Are startups trying to connect the brain to the physical world too?
Neurotech startups are increasingly treating computer control as the first layer of a larger control system. Once neural intent can reliably become a digital command, the same output can operate wheelchairs, robotic limbs, environmental controls, phones and AI software.
NeuroXess offers one of the clearest demonstrations of this direction. Its implanted BCI has been connected to exoskeleton gloves, smart wheelchairs, home devices and robotic systems. In one reported case, a 29-year-old person with high-level paralysis used the BCI together with functional electrical stimulation to regain enough intentional control to eat and draw. The company has also demonstrated two implanted users playing Chinese chess remotely while separated by roughly 800 kilometers.
Synchron describes its system more broadly as a motor neuroprosthesis intended to restore meaningful control of digital devices. Paradromics recently obtained FDA authorization within its clinical study to expand access to personal computing devices. CorTec showed that a participant implanted primarily for post-stroke rehabilitation could use the same system for thought-based computer control.
The common goal is a neural command layer that can work across many ordinary devices.
This chart, featured in our neurotechnology market deck, shows why Neuropace is winning in neurotechnology
Are neurotech startups building treatments rather than computer interfaces?
Neurotech startups are increasingly building treatments. Some of the most consequential neurotech being developed today looks less like futuristic computing and more like a new generation of programmable medicine. Startups are developing implants that stimulate specific brain circuits for depression, stroke rehabilitation, epilepsy and potentially other neurological disorders.
Motif Neurotech's first target is treatment-resistant depression. Its DOT device is designed to deliver electrical stimulation to a brain network associated with executive function through a miniature implant that can be wirelessly powered. The FDA cleared the company to begin its first clinical trial in 2026, moving the technology from preclinical development into testing in patients.
CorTec is pursuing chronic stroke recovery with a device that both records cortical activity and provides stimulation during rehabilitation. By April 2026, three participants had been implanted in its NIH-funded study, and the company reported that an earlier participant regained upper-limb abilities after conventional recovery had plateaued.
INBRAIN ultimately wants to use high-resolution graphene electronics for precision neurological therapy. The broader direction is toward stimulation that can eventually respond to the patient's neural state rather than operate as a fixed electrical treatment.
Why is depression attracting implantable neurotech startups?
Depression is becoming a serious neurotechnology target because existing brain stimulation already provides evidence that electrical intervention can change psychiatric symptoms, while today's procedures leave room for smaller, more precise and more convenient devices. Startups therefore do not have to prove from zero that the brain can be electrically treated; they have to make stimulation easier to deploy and more responsive.
Motif Neurotech illustrates that strategy. Its DOT system is about the size of a pea and is intended to be placed through a comparatively limited procedure rather than the larger implanted pulse-generator architectures associated with traditional deep-brain stimulation. Wireless external power also removes the need for a conventional implanted battery.
The target population is substantial even before considering broader depression. Motif cites roughly three million Americans living with treatment-resistant depression, and estimates that about one-third of people with depression do not respond adequately to pharmaceutical intervention.
The larger opportunity is adaptive stimulation, not simply implant miniaturization.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, shows annual funding in neurotechnology startups
Can non-invasive neurotech do anything useful beyond measuring brainwaves?
Non-invasive neurotech is currently strongest where relatively coarse neural information is enough, and startups are already finding useful applications in sleep modulation, cognitive-state tracking and clinical EEG monitoring.
Elemind's sleep headband records EEG, identifies the user's brain rhythms and delivers precisely timed acoustic stimulation. The company reports that 76% of participants in its clinical testing fell asleep faster with the system, with an average reduction in sleep-onset time of 48% among responders. The commercial device currently sells for $399.
That product also shows why sleep has become one of the clearest consumer neurotech markets. Elemind continuously analyzes EEG signals and times acoustic stimulation according to the user's brain rhythms, with functions designed both to accelerate initial sleep and help users return to sleep after waking. It is also developing stimulation aimed at slow waves during deep sleep. A conventional sleep tracker mostly tells you what happened afterward; Elemind is trying to influence sleep while it is occurring.
Neurable has embedded EEG sensors into conventional-looking headphones. Its MW75 Neuro LT, priced at $499, turns electrophysiological measurements into estimates of focus, cognitive strain, recovery and other daily brain-health indicators. Epitel targets a more clinical problem with the REMI Remote EEG Monitoring System, which uses small wearable wireless sensors and cloud software to detect electrographic seizures.
Ceribell shows how large that clinical category can become, even though it has already progressed beyond startup status into a public company. Its rapidly deployable EEG system is used in intensive-care units and emergency departments; by the second quarter of 2026 it reported 712 active accounts, $28.1 million in quarterly revenue and 33% year-over-year growth.
The limitation remains bandwidth. Scalp EEG works much better for detecting brain states, sleep and seizures than for decoding detailed speech or movement.
Are better materials becoming as important as better AI in neurotech?
Better materials are becoming just as important as better decoding in neurotech because brilliant software is useless if an electrode damages tissue, moves relative to neurons or gradually loses a stable signal. A distinct group of startups is consequently rebuilding the physical brain-electronics interface.
INBRAIN uses graphene rather than conventional metal electrodes. Its first-in-human study enrolled ten people undergoing brain-tumor surgery, with eight ultimately receiving the interface during surgery. Investigators reported no device-related perioperative adverse events through discharge and obtained usable datasets from all eight treated participants. The electrodes were able to capture high-frequency neural activity and speech-related patterns during awake procedures.
Axoft is pursuing extremely soft polymer implants intended to behave more like brain tissue than rigid electronics. The company says its material is roughly one million times softer than conventional rigid electronics while supporting very high electrode density, and its architecture is intended for bidirectional communication with deep or surface brain regions.
Precision Neuroscience attacks the same biological constraint differently with an ultrathin surface array designed to sit on the cortex rather than penetrate it. NeuroXess uses flexible subdural electrodes. Much of the current BCI race is therefore about making interfaces the brain can tolerate for years.
| Materials approach | Startup | What it is trying to solve |
|---|---|---|
| Graphene electrodes | INBRAIN | High-resolution sensing with thin, flexible electronics |
| Soft polymers | Axoft | Mechanical mismatch between brain tissue and implants |
| Thin cortical film | Precision Neuroscience | High-density recording without penetrating cortex |
| Flexible subdural interface | NeuroXess | Neural access with less tissue penetration |
This chart, featured in our neurotechnology market deck, compares the main business model options for neurotechnology device platforms
Are neurotech startups building platforms or single-purpose medical devices?
The most ambitious neurotech startups are currently building platform architectures but entering the clinic through one narrow indication. Regulators and physicians need a specific disease and measurable benefit, while the same underlying hardware may eventually serve multiple neurological problems.
CorTec makes this strategy explicit. Brain Interchange is one implant capable of recording and stimulating the cortex, but its first major therapeutic indication is chronic stroke rehabilitation. The same hardware has already demonstrated computer control, and the FDA has separately recognized its potential communication application.
Paradromics starts with severe communication impairment, yet the fundamental product is a high-data-rate neural interface capable of generating speech, text and computer commands. INBRAIN's graphene platform is initially being validated around neurosurgery and neurological treatment rather than a universal BCI. Axoft is even further down the stack, developing implant materials, electronics, surgical tools and neural-decoding software that could theoretically support multiple therapies.
The recurring strategy is to prove one narrow clinical use before expanding the platform.
Is AI becoming the product in neurotech, or just the decoder?
AI is becoming an important layer of neurotechnology, but neural access remains the scarce asset. Startups increasingly use machine learning to turn noisy biological signals into intended movement, speech, cognitive states or stimulation decisions, yet better algorithms cannot fully compensate for weak or unstable input data.
Paradromics uses machine learning to interpret neural activity and convert intended communication into speech, text or computer commands. NeuroXess combines implanted recordings with its XessOS software layer to translate neural intention into commands for computers, AI assistants and physical devices. Axoft is developing what it calls a Brain Foundation Model intended to improve neural interpretation over time.
The consumer side follows the same pattern. Neurable converts EEG into cognitive metrics, while Elemind adapts stimulation to each user's measured brain rhythms. Clinical EEG platforms similarly apply algorithms to enormous streams of electrophysiological data so clinicians do not have to interpret every second manually.
The strongest advantage may come from pairing decoding software with proprietary, high-quality neural data.
If you want more recent data on this point, please see our latest neurotechnology market report.
This chart, featured in our neurotechnology market deck, breaks down revenue by customer segment in the neurotechnology market
Is China catching up with US neurotech startups?
China is already producing serious implantable BCI competitors, and the gap is no longer large enough to dismiss the market as a US-only race. NeuroXess in particular has progressed from demonstrations toward repeat human implantation, registration-oriented trials and manufacturing infrastructure.
The company reported its first fully implanted, fully wireless clinical system in late 2025 and disclosed a second clinical case in 2026. That participant combined neural decoding with functional electrical stimulation to perform practical tasks including eating and drawing. NeuroXess subsequently launched a GCP registration clinical trial and entered China's innovative-medical-device special review pathway.
Its product development also looks increasingly industrial rather than purely academic. NeuroXess says it has established manufacturing capacity capable of supporting production at the ten-thousand-unit level, alongside dedicated chip-development operations and hospital partnerships across multiple Chinese provinces.
US companies remain exceptionally strong: Neuralink has driven public awareness and human BCI deployment, Synchron has a comparatively mature endovascular approach, Precision has obtained FDA clearance for its cortical array, and Paradromics has entered long-term human implantation. China is nevertheless already part of the core BCI race.
What are neurotech startups not building successfully yet?
Neurotech startups are not yet building a mass-market brain interface that combines high bandwidth, trivial implantation, multi-year stability, autonomous operation and proven clinical benefit. Each leading architecture solves only part of that equation.
Intracortical systems can capture rich signals but face demanding neurosurgery and long-term biological stability. Surface interfaces reduce penetration but may surrender some single-neuron resolution. Synchron avoids direct brain surgery through blood vessels but captures signals at greater distance. Non-invasive EEG eliminates surgery almost completely but provides much lower spatial resolution.
Durability remains particularly important. Neural interfaces must preserve signal quality despite biological tissue responses, electrode movement, mechanical stress and years of use. Recent reporting on the BCI industry continues to identify signal degradation and implant longevity as central unresolved problems. That explains the attention being paid to graphene, soft polymers, ultrathin films and non-penetrating interfaces.
Clinical usefulness is the other major hurdle. A commercial medical device must improve independence or health enough to justify surgery, training, hardware support and reimbursement.
This chart, featured in our neurotechnology market deck, shows how brain sensing wearable technology has evolved over time
So where is neurotech startup activity actually concentrating?
Neurotech startup activity is concentrating around restoring lost neurological function and treating disease, while consumer brain enhancement remains a much smaller and less capable category than the publicity around BCIs can imply. The highest-intensity engineering work is happening where the benefit of accessing the nervous system can justify the inconvenience or risk of the technology.
For severe paralysis and speech loss, startups are developing implanted BCIs because even complex surgery may be acceptable if the result is independent communication. For stroke and treatment-resistant depression, companies are developing programmable stimulation because a meaningful therapeutic improvement can justify an implanted device. For seizure detection, sleep and cognitive tracking, less invasive wearable sensors are sufficient because the task requires less neural information.
The underlying technology stack is consequently developing at several levels simultaneously. Electrode companies are making neural interfaces softer and denser. Implant developers are reducing surgical burden. Decoding teams are extracting richer intentions from neural signals. Therapeutic startups are closing the loop with stimulation. Application developers are connecting those outputs to computers, AI assistants and physical devices.
| Where activity is strongest | What is being built | Maturity today |
|---|---|---|
| Paralysis and communication | Implantable BCIs | Human clinical trials |
| Stroke rehabilitation | Recording + cortical stimulation | Early human trials |
| Psychiatric treatment | Miniaturized neuromodulation implants | Entering clinical trials |
| Neurological monitoring | Wearable EEG + automated interpretation | Commercial |
| Sleep and cognition | EEG wearables + feedback/stimulation | Consumer products |
| Neural-interface hardware | Graphene, polymers, cortical films, chips | Research to early clinical use |
Neurotech: what are startups building now?
Neurotech startups are now building a new interface layer between nervous systems and machines, but the near-term industry is medical rather than transhuman. The strongest products are designed to restore speech and computer control to people with paralysis, stimulate damaged or dysfunctional brain circuits, monitor neurological patients continuously, and improve the physical interface between electronics and neural tissue.
The most important change is the move from isolated neural decoding toward complete systems. Paradromics is building an implanted communication system around its electrodes. Synchron is combining an endovascular sensor with digital-device control. CorTec is using one implant for neural recording, stimulation and potentially communication. Motif is miniaturizing psychiatric stimulation. INBRAIN and Axoft are redesigning the material layer. Elemind is turning neural sensing into real-time consumer intervention.
That also shows where the limits still are. The industry is nowhere close to replacing keyboards for healthy consumers, uploading knowledge or delivering general cognitive superpowers. High-bandwidth interfaces still require invasive hardware, while non-invasive systems currently extract much coarser information.
The real neurotech wave is narrower and more credible than the science-fiction version. Startups are building specialized interfaces that read increasingly useful neural signals, write information back into the nervous system and connect those capabilities to a specific medical or behavioral outcome. If the current clinical programs work, the first breakthrough will be that neurological functions once considered permanently lost or extremely difficult to treat become electronically addressable.
If you want more recent data on this point, please see our latest neurotechnology market report.
In our neurotechnology market deck, we identify pain points entrepreneurs should prioritize
OUR METHODOLOGY
The question “What are neurotech startups actually building now?” sounds simple, but the industry is unusually easy to misread. Brain-computer interfaces receive most of the attention, while therapeutic implants, wearable EEG, neural materials, decoding software and clinical monitoring systems are developing at the same time. We therefore approached the subject as a mapping exercise rather than a collection of prominent companies.
We broke the question into the dimensions that most clearly separate what is happening across the sector: what function the technology performs, how it accesses the nervous system, what application it is being built for, and how far it has progressed from research toward real use. We then examined each dimension separately and aggregated the strongest recent evidence before drawing conclusions across them.
We gave the most weight to signals that show technology moving in the real world: human implantation, registered clinical studies, regulatory decisions, repeated use in patients, commercially available products and disclosed operating data. Prototype demonstrations and company roadmaps were useful for understanding direction, but they carried less weight when judging where neurotech is actually progressing today. For product architecture and development plans, we used first-hand company information; wherever possible, clinical and regulatory progress was checked against FDA records, ClinicalTrials.gov, academic institutions or public filings.
We also avoided ranking technologies through a single headline metric. Electrode counts, for example, say little on their own when one system penetrates the cortex, another rests on its surface and another reaches the brain through a blood vessel. We compared approaches through the trade-offs that actually distinguish them: the richness of the neural information available, the burden of accessing it, the stability required over time and the usefulness of the resulting system.
The same principle guided our view of applications and geographic competition. We looked for clusters of independent evidence rather than allowing one exceptional demonstration to define a trend. An area became important in our analysis when several teams were committing serious engineering and clinical work to it, and when those efforts were producing increasingly concrete milestones.
The final picture comes from that aggregation. We built the conclusion from recent developments across companies, technologies, clinical programs and regulatory stages. That produced a grounded picture of neurotech today: a field concentrating heavily on restoring function, treating neurological disease, improving neural access and turning brain signals into useful systems.
Key sources used for this analysis include: Neuralink on the N1 architecture and PRIME study progress, Neuralink's PRIME study documentation, Synchron on the Stentrode architecture, ClinicalTrials.gov on Synchron's INTENT study, Paradromics on its first long-term Connexus implantation, ClinicalTrials.gov on the Connect-One study, the FDA 510(k) record for Precision Neuroscience's Layer 7-T cortical electrode, ClinicalTrials.gov on CorTec's Brain Interchange stroke study, CorTec on its communication Breakthrough Device designation, ClinicalTrials.gov on Motif Neurotech's RESONATE trial, Motif Neurotech's clinical-trial authorization updates, INBRAIN on its graphene interface technology, ClinicalTrials.gov on INBRAIN's first-in-human study, NIHR Manchester on the first-in-human graphene interface results, Axoft on its soft polymer implants and neural-decoding platform, NeuroXess on its implanted BCI platform and decoding results, Elemind on its commercial EEG sleep headband, Neurable on the MW75 Neuro LT, Epitel on the REMI wearable EEG system, and Ceribell's SEC filing for second-quarter operating data.
This chart, featured in our neurotechnology market deck, breaks down revenue by region across Europe, Asia, North America, Africa, and South America in the neurotechnology market
Related blog posts
- The most recent funding news in the neurotechnology market
- Which brain-computer interface startup is growing the fastest?
- What are the top startups in the neurotechnology market?
- The main fundraising trends in the neurotechnology market
- How strong is fundraising in the neurotechnology market right now?
- The evolution of funding activity in the neurotechnology market
